Guggenheim Remains Positive on Zoetis (ZTS) as CFO Departs for Valeant (VRX)

August 22, 2016 11:16 AM EDT
Get Alerts ZTS Hot Sheet
Price: $53.97 +0.88%

Rating Summary:
    13 Buy, 5 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ZTS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Guggenheim is out with commentary on recent CFO changes at Zoetis (NYSE: ZTS) and Valeant. The firm rates Zoetis at Buy with a price target of $60.

Analyst Louise Chen comemnted, In Specialty Pharma it seems as if conservation of mass applies to senior leadership changes within the industry. Yesterday evening, Zoetis announced that Glenn David, SVP of Finance Operations, has been named CFO. The former CFO, Paul Herendeen, has joined Valeant Pharma (NYSE: VRX). We view this as very positive for Valeant given Paul's demonstrated record of success with ZTS and Warner Chilcott (acquired by Allergan), but we think most of Paul's work to increase the efficiency of ZTS's earnings potential has been completed. Therefore, we believe Glenn David should be experienced enough to continue Paul's work going forward. Glenn was acting CFO while ZTS was transitioning from its first CFO to Paul Herendeen. Therefore, he is known to the investment community and the feedback was positive regarding his work.

We had a chance to speak to Juan Ramon, CEO, Glenn David, CFO, Steve Frank, IR, as well as other members of the management team at ZTS this morning. In summary, the team was enthusiastic that Glenn is the right person to take Paul's place, and the financial guidance given about two and half weeks ago remains intact, the analyst noted.

For an analyst ratings summary and ratings history on Zoetis Inc. click here. For more ratings news on Zoetis Inc. click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Changes

Related Entities

Earnings, Louise Chen, Guggenheim

Add Your Comment